Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
Conditions
Brief summary
The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and participants with atopic dermatitis. This study consists of four parts: Part A is a single ascending dose (SAD) study, once sufficient safety and PK data are obtained from the SAD cohorts, the SMC will determine the dosage of initial cohort in Part B, which consists of three multiple ascending doses (MAD) cohorts of QLS12010 Capsules. Part C is a randomized, open-label, two-cycle, crossover food effect study under fasting and fed (high-fat meal) conditions. Part D is to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and preliminary efficacy of QLS12010 Capsules following multiple oral administrations in adult participants with atopic dermatitis (AD).
Interventions
DRUGQLS12010
QLS12010 oral capsule(s)
DRUGPlacebo
Matching placebo oral capsule(s)
Sponsors
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
for Parts A-C: * Males and females aged 18-45 (inclusive), * Weight: ≥ 50 kg for males and ≥ 45 kg for females, body mass index (BMI): 18.0-30.0 kg/m2 (inclusive), Inclusion Criteria for Part D: * Female or male participants between the ages of 18 to 75 years of age. * Chronic AD diagnosed by the criteria of Hannifin and Rajka that has been present for at least 6 Months before the Screening Visit. * At screening and baseline: EASI score ≥ 16, vIGA-AD™ score ≥ 3, and BSA affected by AD ≥ 10%; * The weekly mean score of PP NRS ≥ 4 prior to the first administration (with assessment results for at least 4 days during the week before the first administration \[D-7 to D-1\]); * As judged by the investigator, within 6 months prior to screening, the patient had an inadequate response to topical medication therapy. General
Exclusion criteria
* Participants with diseases that should be excluded as judged by the investigator at screening, including but not limited to the nervous system, psychiatric system, cardiovascular system, blood and lymphatic system, immune system, respiratory system, digestive system, urinary system, metabolic and skeletal system disorders, * The 12-lead ECG at screening shows QTcF (QT corrected using Fridericia's formula) \> 450 ms. If QTcF is \> 450 ms, the 12-lead ECG should be repeated 2 more times (at least 3 min apart), and the mean of the 3 measurements will be used to determine whether the participant meets the inclusion criteria, * Participants who smoke more than 5 cigarettes per day on average within 6 months before screening or are currently using e-cigarettes, * Participants who consume more than 14 units of alcohol per week (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine) within 6 months before screening or have a positive breath alcohol test at screening, * Participants who have donated more than 400 mL of blood within 3 months or more than 200 mL of blood within 4 weeks before screening, or plan to donate blood during the study, * Participants who have received any strong inhibitor or inducer of CYP3A4 within 4 weeks before screening, * Participants who have received any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks before the first dose or 5 half-lives (whichever is longer). Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0 | up to approximately 1 month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] | up to approximately 14 days | — |
| Maximum observed plasma concentration (Cmax) | up to approximately 1 month | — |
| Time to maximum observed plasma concentration (Tmax) | up to approximately 1 month | — |
| Terminal elimination half-life (t1/2) | up to approximately 1 month | — |
| Apparent clearance (CL/F) | up to approximately 1 month | — |
| Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)] | up to approximately 1 month | — |
| Mean residence time (MRT) | up to approximately 1 month | — |
| Changes and percentage changes from baseline in Eczema Area and Severity Index (EASI) scores | at Weeks 1, 2, 3, 4, 5, and 6 | The minimum EASI score is 0, and the maximum EASI score is 72. A score of 0 indicates clear or no eczema; a greater score indicates more severe disease. |
| Changes and percentage changes from baseline in Investigator's Global Assessment (IGA) scale | at Weeks 1, 2, 3, 4, 5, and 6 | The IGA5-point scale ranges from 0 (clear) to 4 (severe AD). A decrease in score indicates an improvement in signs and symptoms. |
| Changes and percentage changes from baseline in weekly mean scores of Peak Pruritus Numerical Rating Scale (PP NRS) | at Weeks 1, 2, 3, 4, 5, and 6 | The PP NRS is a single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 h based on the following question: 'On a scale of 0 to 10, with 0 being no itch and 10 being worst itch imaginable. |
| Changes and percentage changes from baseline of body surface area (BSA) affected by lesions | at Weeks 1, 2, 3, 4, 5, and 6 | BSA assessment estimates the area of skin lesions in each part of the body, with one palm unit of the patient taken as 1% of the body surface area. |
| Apparent volume of distribution (Vz/F) | up to approximately 1 month | — |
Countries
China
Contacts
Primary ContactHaiyan Li, M.D.
Backup ContactWenhui Wang, M.D.
Outcome results
None listed